Orient Pharma Co (ROCO:4166) Other Stockholders Equity: NT$5 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4166 Orient Pharma Co Ltd ROCO:4166
61 GF Score
Price NT$26.15
GF Value NT$45.26
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Orient Pharma Co Other Stockholders Equity?

Orient Pharma Co ROCO:4166 -1.88% 61 Other Stockholders Equity is NT$5 Mil as of Dec. 2025. GuruFocus rates ROCO:4166 with a GF Score™ of 61/100 and a GF Value™ of NT$45.26 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Orient Pharma Co's Other Stockholders Equity for the quarter that ended in Dec. 2025 was NT$5 Mil.

Orient Pharma Co's quarterly Other Stockholders Equity increased from Jun. 2025 (NT$6 Mil) to Sep. 2025 (NT$6 Mil) but then declined from Sep. 2025 (NT$6 Mil) to Dec. 2025 (NT$5 Mil).

Orient Pharma Co's annual Other Stockholders Equity increased from Dec. 2023 (NT$-4 Mil) to Dec. 2024 (NT$6 Mil) but then declined from Dec. 2024 (NT$6 Mil) to Dec. 2025 (NT$5 Mil).

Orient Pharma Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Orient Pharma Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orient Pharma Co Other Stockholders Equity Chart

Orient Pharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.60 -2.89 -3.83 6.05 5.08

Orient Pharma Co Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.05 7.18 6.00 6.35 5.08
ROCO:4166
61GF Score
Orient Pharma Co Ltd ROCO:4166
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orient Pharma Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$5 Mil mean?
Orient Pharma Co (ROCO:4166) has a Other Stockholders Equity of NT$5 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Orient Pharma Co and its competitors.
Is Orient Pharma Co's Other Stockholders Equity too high?
Orient Pharma Co's current Other Stockholders Equity is NT$5 Mil. Overall, Orient Pharma Co has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Other Stockholders Equity compare to ZTS and UTHR?
Orient Pharma Co's Other Stockholders Equity of NT$5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Orient Pharma Co and its competitors. Orient Pharma Co's current Other Stockholders Equity is NT$5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.26, compared to a current price of NT$26.15 — trading 42.2% below its estimated fair value. The current Other Stockholders Equity is NT$5 Mil. Orient Pharma Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Other Stockholders Equity is NT$5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued. The current stock price of NT$26.15 is trading 42.2% below its estimated GF Value™ of NT$45.26. GuruFocus considers Orient Pharma Co to be Significantly Undervalued.

Key valuation signals for ROCO:4166:

  • Other Stockholders Equity: NT$5 Mil
  • GF Value™: NT$45.26 vs. price of NT$26.15 (42.2% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orient Pharma Co Business Description

Address No. 8, Kehu 1st Road, Huwei Town, Yunlin County, Central Science Park, Taipei, TWN, 106
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
61GF Score

Get the complete analysis for ROCO:4166

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.15
Price
NT$45.26
GF Value